| Literature DB >> 32322544 |
Uloma Ubani-Ukoma1, Anuj Chauhan2, Gregory Schultz3, Daniel J Gibson3.
Abstract
In vitro screening and testing of drugs and devices is necessary, but in vitro conditions differ greatly from those found in vivo. These differences can lead to false promises of efficacy, or can hide problems of tissue compatibility. Models with ex vivo tissues can be highly valuable bridges which provide relevant matrices for testing [1], [2], [3], [4], [5], [6], [7], [8], [9]. Ex vivo tissue models which are closer both biochemically and biophysically can provide useful feedback in a more time- and cost-efficient manner. Herein we describe an ex vivo corneal model for use in drug delivery testing and corneal infection modeling [10]. The protocol covers the tissue harvesting, sterilization, inoculation, and bacterial load quantification. We envision that the model can be used to study bacterial physiology on metabolizable matrices and to study the direct effects of microbial colonization on the cornea's integrity and clarity.•Devitalized cornea.•Non-submersed conditions.•Contact lens compatible.Entities:
Keywords: Bacterial keratitis; Ex vivo tissue models; Native matrix models; Ocular drug delivery
Year: 2020 PMID: 32322544 PMCID: PMC7160597 DOI: 10.1016/j.mex.2020.100876
Source DB: PubMed Journal: MethodsX ISSN: 2215-0161
Fig. 1(A) A frozen rabbit eye. (B) Biopsy punch placed on the eye with slight pressure. (C) The eye showing the cut outline made by the punch. (D) Removal of epithelium and superficial stroma. (E) Exposure of stroma with partially removed epithelium. (F) Exposed stroma with flap. G) Excised cornea with iris. (H) Removal of the iris and ciliary body. (I) Corneoscleral button showing removed epithelium, superficial stroma and iris (flap was excised for all corneas used).
Fig. 2A visual outline of the model. (A) The sterilized cornea is placed into a supporting mold, and (B) is filled with soft agar. (C) The agar-filed cornea is placed on a dish with soft agar and inoculated. (D) The inoculum is allowed to establish for a duration dependent upon the experiment, and the experiment is then performed. (E) At each time point, the contact lens is removed and the cornea is collected by biopsy. (F) The agar is removed and (G) the cornea is assayed for total viable bacteria.
Fig. 3Screening sterilization techniques. A large number of potential sterilants can be assessed rapidly via (A) a gross assessment of tissue toleration. (B) The efficacy can be grossly assessed by observable turbidity after incubating treated corneas in growth medium. Solutions appearing to be grossly effective can be further assessed quantitatively by measuring (C) turbidity via spectrophotometry.
Result of 16S rRNA genetic sequencing of infected corneas.
| Decontamination technique | Level of identification% | Contaminating organism |
|---|---|---|
| 10% Povidone Iodine | 99 | None |
| 5% Povidone Iodine | 90 | None |
| 10% Povidone Iodine and soaking in TSB | 83 |
Fig. 4Example of successful colonization. (A) Viable CFU/ml for both P. aeruginosa (PAO1) and S. aureus (SA35556). H&E can be used to visualize (B) P. aeruginosa (PAO1) and (C) S. aureus (SA35556). (D) An image of a clean cornea vs. one infected with (E) P. aeruginosa (PAO1) or F) S. aureus (SA35556).
Specifications Table
| Subject Area | Immunology and Microbiology |
| More specific subject area | Ocular Drug Delivery |
| Method name | |
| Name and reference of original method | Berkowski, W. M. et al. Assessment of Topical Therapies for Improving the Optical Clarity Following Stromal Wounding in a Novel |
| Resource availability | If applicable, include links to resources necessary to reproduce the method (e.g., data, software, hardware, reagent) |